Home » Myriad Genetics Submits Vivecon IND
Myriad Genetics Submits Vivecon IND
Myriad Genetics has filed an investigational new drug application (IND) with the FDA to begin human clinical trials with Vivecon, a potential AIDS treatment.
Vivecon is a small-molecule drug candidate designed to inhibit viral maturation and is the first antiviral drug candidate Myriad has advanced to human clinical trials.
The first planned Phase I trial for Vivecon will assess the pharmacokinetics, absorption and tolerability of the compound. If the trial is successful, the company will begin a Phase IIa multiple ascending-dose trial, Myriad said.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May